Hundreds of Cyclists to Ride Through Durham, NH, June 21–22, to Raise Funds for ALS Research
Durham, NH June 16, 2025 --( PR.com )-- On June 21, the streets of Durham, NH will once again fill with the energy and determination of hundreds of cyclists participating in the 23rd annual Tri-State Trek, a powerful and emotional bike ride raising funds for cutting-edge ALS research at the ALS Therapy Development Institute ( ALS TDI ).
Founded in 2003 with just 16 riders, the Trek has grown into a beloved New England tradition expected to draw more than 400 participants this year. The weekend-long ride kicks off and concludes in Durham, looping through scenic routes in Massachusetts and Maine. With one- and two-day ride options ranging from 30 to 100 miles per day, the Trek is open to both avid cyclists and newcomers looking to support an vitally important cause – ending ALS.
'Whether you're an experienced cyclist or someone hopping on a road bike for the first time, the Tri-State Trek is all about community, compassion, and taking action against ALS,' said Carol Hamilton, Senior Vice President of Fundraising and Development at ALS TDI. 'People leave this event with a sense of purpose—and with a new family.'
ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative condition with no known cure. The ALS Therapy Development Institute, based in Watertown, MA, is the world's most comprehensive nonprofit biotech focused 100% on discovering treatments for ALS.
'ALS is relentless. The average patient only lives three to five years after diagnosis,' said Dr. Fernando Vieira, CEO and Chief Scientific Officer of ALS TDI. 'Events like the Tri-State Trek fuel the research needed to bring real treatments to people living with ALS today.'
While many riders have a personal connection to ALS, the Trek is open to all. Local residents are encouraged to cheer on riders, join as volunteers, or get involved virtually. The event offers extensive photo and interview opportunities with cyclists, families, and researchers who are committed to ending ALS.
Media Opportunities:
What: 23rd Annual Tri-State Trek
When: June 21–22, 2025 (riders depart both mornings from Durham)
Where: Start/finish line at University of New Hampshire, Durham, NH
Visuals: Mass starts, team jerseys honoring loved ones, finish line celebrations, rider interviews
Interviews Available: Local riders, ALS patients/families, ALS TDI researchers and leadership
To learn more about the Tri-State Trek, visit https://tst.als.net/ .
For media inquiries, ride-day access, or to schedule interviews in advance, please contact:
Meghan Lawlor
[email protected] | 978-729-2961
About the ALS Therapy Development Institute
The ALS Therapy Development Institute (ALS TDI) and its researchers discover and develop potential treatments for ALS. It is the world's first and largest nonprofit biotech focused 100 percent on ALS research. Led by drug development experts and people with ALS, ALS TDI understands the urgent need to slow and stop this disease.
Based in Watertown, MA, ALS TDI has more than 30 full-time, industry-trained drug development experts on staff. ALS TDI is internationally recognized as a leader in preclinical and translational ALS research, and partners with pharmaceutical companies and biotech organizations all around the world. Rated a four-star nonprofit on Charity Navigator, ALS TDI spends 87 cents of every dollar raised on finding effective treatments and cures for ALS. Visit https://www.als.net/ for more information.
Contact Information:
ALS Therapy Development Institute
Meghan Lawlor
(978)729-2961
Contact via Email
www.als.net
Read the full story here: Hundreds of Cyclists to Ride Through Durham, NH, June 21–22, to Raise Funds for ALS Research
Press Release Distributed by PR.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
18 hours ago
- Associated Press
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
Watertown, MA June 24, 2025 --( )-- The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. This milestone is made possible through a new supply agreement with Axol Bioscience Ltd., a leading provider of iPSC-derived cells and services. These iPSC lines, developed by ALS TDI from samples generously donated by participants in the ALS Research Collaborative (ARC) Study, represent both genetic and sporadic forms of ALS. They include key ALS-associated mutations such as C9orf72, SOD1, and TDP-43, and will be used to generate ALS-relevant cell types—including motor neurons, microglia, and astrocytes—for use in drug discovery and disease modeling. The goal of this collaboration is to provide high-quality research tools to the global scientific community, including academic and pharmaceutical researchers, to help further the understanding and development of treatments for ALS. 'This is a major step forward for ALS research,' said Dr. Fernando Vieira, CEO and Chief Scientific Officer at ALS TDI. 'By making these iPSC-derived cells broadly accessible through Axol's infrastructure, we are ensuring that the contributions of people with ALS who shared their samples and data through ARC can drive discoveries in labs across the globe.' ALS TDI has built one of the most comprehensive collections of ALS-specific iPSCs available today. These cells are derived from real people living with ALS, many of whom also shared clinical data, creating a uniquely valuable resource for understanding disease mechanisms and testing potential treatments. Through this agreement, Axol will manufacture and distribute iPSC-derived cells to academic and industry researchers worldwide, ensuring quality, consistency, and scalability. The goal, to accelerate progress across the ALS field by providing powerful, human-relevant tools that better reflect the diversity and complexity of the disease. 'Collaborating with ALS-TDI allows us to broaden access to highly disease-relevant iPSC models of ALS, which are vital for understanding disease mechanisms and accelerating therapeutic discovery for patients and their families,' said Liam Taylor, CEO of Axol Bioscience. 'This partnership aligns with our mission to build and enable better human disease models by providing high-quality, human-relevant cells and models that advance neuroscience research and drug development.' ALS TDI extends its deepest thanks to every person living with ALS who contributed to this effort. Their willingness to share samples and data through the ARC Study has made this breakthrough possible. To learn more about the ALS Research Collaborative, visit For more information, please contact: Axol Bioscience Duncan Borthwick [email protected] ALS Therapy Development Institute Fernando Vieira [email protected] About Axol Bioscience Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. Axol has a deep connection with the ALS research community and works to support the creation of more human relevant in vitro models to accelerate discovery and therapeutic development. About ALS Therapy Development Institute (ALS TDI) The ALS Therapy Development Institute (ALS TDI) is the world's first and largest nonprofit biotech dedicated solely to discovering and developing effective treatments for ALS. Based in Watertown, Massachusetts, ALS TDI runs a state-of-the-art research center and leads the ALS Research Collaborative (ARC)—one of the most comprehensive and longest-running natural history studies in ALS. Through innovative, patient-driven science, ALS TDI is working to end ALS for everyone affected by this devastating disease. Contact Information: ALS Therapy Development Institute Meghan Lawlor (978)729-2961 Contact via Email Read the full story here: ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research Press Release Distributed by
Yahoo
18 hours ago
- Yahoo
Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best biotech stocks to invest in now. On June 3, Amylyx Pharmaceuticals announced that the US FDA granted Fast Track designation to AMX0114. AMX0114 is an investigational antisense oligonucleotide/ASO that is specifically designed to target calpain-2. This protein is believed to be a significant contributor to axonal degeneration, which is a key driver in the progression of amyotrophic lateral sclerosis/ALS. ALS is a rapidly progressive and fatal neurodegenerative disorder with limited therapeutic options. The Fast Track designation is a crucial step for Amylyx in its mission to develop treatments for ALS. The FDA's decision acknowledges both the severity of ALS and the encouraging preclinical data supporting AMX0114's potential. A medical scientist in a lab coat gazing at a microscopic view of a drug in development. Calpain-2 is a calcium-activated protease. Research has indicated that overactive calpain-2 activity might accelerate disease progression in ALS and other neurodegenerative conditions by causing the degeneration of axons, which are vital for transmitting signals between neurons and muscles. Preclinical studies of AMX0114 have demonstrated improved neuronal survival and reduced levels of extracellular neurofilament light (NfL), which is a biomarker for neuronal damage across various disease models. AMX0114 was also well-tolerated in preclinical safety studies. Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is a clinical-stage pharmaceutical company that discovers and develops treatments for neurodegenerative diseases and endocrine conditions in the US. While we acknowledge the potential of AMLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.


USA Today
a day ago
- USA Today
Eric Dane explains why he feels 'lucky' amid ALS battle: See video
"Euphoria" actor Eric Dane said he is grateful and privileged to have financial stability amid his ongoing battle with ALS, but warned that many other American families are not. The "Grey's Anatomy" alum spoke at U.S. Health Secretary Robert F. Kennedy Jr.'s hearing to discuss the Monday, June 23 announcement that several health insurance companies plan to simplify and reduce prior authorizations over the next year and a half. UnitedHealthcare, Blue Cross Blue Shield and Kaiser Permanente were among the companies that aim to streamline the common process of vetting requests before allowing doctors to bill for medical services or prescriptions. In April, the 52-year-old San Francisco native revealed he was diagnosed with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. At Monday's press conference, Dane applauded the insurance industry for coming together to offer other ALS patients "more certainty, faster answers and more hopes for recovery." "Some of you may know from TV shows such as 'Grey's Anatomy' which I play a doctor, but I am here to today to speak briefly as a patient," he said. "When that diagnosis hits and you find out that you're sick, your life becomes filled with great uncertainty. And the worst thing we could do is add even more uncertainty for patients and their loved ones with unnecessary prior authorization." Prior authorization has criticized by many doctors and patients who argue the practice routinely delays or denies care, according to various surveys and government oversight reports. The newly unveiled changes could impact 257 million Americans who are covered by private commercial insurance, Medicare Advantage and Medicaid managed care plans. "Anything we can do to give patients more certainty with fewer delays is a worthwhile endeavor," he said. "I've been fortunate and have the means to access great care. I am lucky. Not everyone is in the same position." Eric Dane says right arm has 'completely stopped working' Last week, Dane shared that his ALS has progressed to the point that his right arm has stopped functioning. "I have one functioning arm," he told Diane Sawyer on a June 16 "Good Morning America" interview. "My left side is functioning. My right side has completely stopped working." The actor said he expects just a few more months before "I won't have my left hand either," which he called "sobering." And while he luckily has not had any issues walking, he added that he's also "worried" about his legs. Dane is arguably best known for playing played the plastic surgeon Dr. Mark Sloan, nicknamed "McSteamy" on ABC's "Grey's Anatomy" from 2006 to 2012. He is also expected to reprise his role as Nate Jacob's father Cal Jacobs in the upcoming third season of HBO's "Euphoria." Contributing: Ken Alltucker and Brendan Morrow, USA TODAY